Codexis Announces Appointment of Sri Ryali as Chief Financial Officer
January 23 2023 - 4:05PM
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company,
today announced the appointment of Sri Ryali as Chief Financial
Officer effective immediately. Mr. Ryali brings 20 years of finance
and commercial experience in life sciences to Codexis. In this
role, Mr. Ryali will lead all aspects of the Company’s financial
operations and will report directly to Dr. Stephen Dilly, President
and Chief Executive Officer of Codexis.
“I am excited to announce the addition of Sri to
Codexis as we continue to build a top executive leadership team
with the strategic acumen, operational experience and commercial
mindset to deliver on our prioritized corporate goals,” said Dr.
Dilly. “2023 is a pivotal year for our Company as we execute
on our plan to focus resources on programs with the greatest
potential for commercial success. Sri’s extensive experience
leading financial organizations within biopharmaceutical companies,
including providing critical leadership and oversight for several
new product launches, will be central to our ongoing efforts to
create long-term shareholder value.”
“Codexis is well positioned to capitalize on its
unique enzyme engineering capabilities, and I am energized by the
opportunity to be part of a talented leadership team as we focus on
realizing the full commercial potential of our platform,” said Mr.
Ryali. “I look forward to working closely with the team as we
execute on our strategy to translate our compelling scientific
capabilities and robust intellectual property portfolio into
growing opportunities that benefit our customers, our shareholders
and potential future patients.”
Most recently, Mr. Ryali served as the Chief
Financial Officer of Eiger BioPharmaceuticals, Inc., a publicly
traded, commercial-stage company, where he was responsible for
finance, investor relations and other general and administrative
functions during a period when the company initiated multiple
late-stage clinical trials and launched its first commercial
product in the United States and Europe. Prior to Eiger
BioPharmaceuticals, Mr. Ryali held roles of increasing
responsibility at Aimmune Therapeutics, Inc., most recently serving
as Vice President of Finance. Prior to this, he was Senior
Director, Financial Planning and Analysis at Jazz Pharmaceuticals,
plc. and held a series of different finance-related positions of
increasing responsibility at Onyx Pharmaceuticals, Inc. and Amgen
Inc. Mr. Ryali earned a B.A. from the University of California, Los
Angeles, with a double major in Economics and Microbiology,
Immunology and Molecular Genetics and an M.B.A. from the UCLA
Anderson School of Management.
About Codexis
Codexis is a leading enzyme engineering company
leveraging its proprietary CodeEvolver® platform to discover
and develop novel, high performance enzymes and biotherapeutics.
Codexis enzymes have applications in the sustainable manufacturing
of small molecule pharmaceuticals and mRNA therapeutics; in the
creation of the next generation of life science tools; and as gene
therapies and oral enzyme therapies. Codexis’ unique enzymes can
drive improvements such as higher yields, reduced energy usage and
waste generation, improved return on capital in manufacturing,
improved sensitivity in genomic and diagnostic applications, and
more efficacious therapeutics. For more information,
visit www.codexis.com.
Forward-Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Codexis, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements include, but are not
limited to, statements regarding the Company’s programs having the
potential to create significant value over the next few years and
the Company’s enzymes being able to drive improvements. You should
not place undue reliance on these forward-looking statements
because they involve known and unknown risks, uncertainties and
other factors that are, in some cases, beyond Codexis’ control and
that could materially affect actual results. Additional information
about factors that could materially affect actual results can be
found in Codexis’ Annual Report on Form 10-K filed with the
Securities and Exchange Commission (“SEC”) on February 28, 2022 and
in Codexis’ Quarterly Report on Form 10-Q filed with the SEC on
November 4, 2022, including under the caption “Risk Factors,” and
in Codexis’ other periodic reports filed with the SEC. Codexis
expressly disclaims any intent or obligation to update these
forward-looking statements, except as required by law.
Investor Relations Contact:
Argot PartnersBrendan Strong/Carrie McKim(212)
600-1902Codexis@argotpartners.com
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jul 2023 to Jul 2024